SCHEMBL1745586

SCHEMBL1745586

CCOC(=O)CCc1c(OC)cc(O)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
CYP4F2 P78329 2/20 0.45
CYP4A11 Q02928 2/20 0.45
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
TNF P01375 3/20 0.44
POLB P06746 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL490672 0.87 POLB (0.47) KDM4EALDH1A1HPGDHSD17B10CYP4F2
SCHEMBL28757991 0.85 HPGD (0.48) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL14925438 0.82 NR1H2 (0.51) KDM4EALDH1A1HPGDGAANR1H2
SCHEMBL2431502 0.81 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL846066 0.81 CNR2 (0.41) KDM4EALDH1A1HPGDHSD17B10CYP4F2
SCHEMBL6136785 0.81 KDM4E (0.48) KDM4EALDH1A1HPGDHSD17B10CYP4F2
SCHEMBL1549816 0.80 CYP4F2 (0.50) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL4257732 0.80 POLB (0.50) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL1746633 0.79 KDM4E (0.48) KDM4EALDH1A1HPGDHSD17B10GLA
SCHEMBL14925318 0.79 KDM4E (0.64) KDM4EALDH1A1HPGDHSD17B10GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR KDM4E 3200/4885ALDH1A1 4258/4885HPGD 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.